Fibroblast heterogeneity has been recognized for decades, but the basis for multiple phenotypes among these cells has been investigated only recently. More than 15 years ago, Bucalla and his colleagues described for the first time a population of fibroblast-like cells among circulating mononuclear blood cells. Subsequently these mesenchymal cells, termed fibrocytes, have been characterized and found to participate in normal and pathological tissue remodelling. In this review, I have attempted to present the evidence generated thus far suggesting that fibrocytes are participants in autoimmune diseases where tissues are injured and undergo remodelling. Aspects of their phenotype suggest that they are well suited to help orchestrate immune responses through mononuclear cell recruitment and their ability to produce inflammatory mediators and extracellular matrix molecules. These attributes also raise the possibility that they might be useful targets against which therapeutic agents might be aimed.
Introduction
Fibroblast heterogeneity has been appreciated for several decades but its biological significance and the basis for cellular diversity remain uncertain. The question of why fibroblasts from distant anatomical regions should exhibit phenotypic divergence is unanswered. Moreover, a mechanism that might account for dissimilar fibroblasts inhabiting specific tissues has not been identified. Three connective tissue depots from which fibroblasts have been studied with considerable rigour include lung, joint and orbital connective tissue [1] [2] [3] [4] . The origins and phenotypic characteristics of the fibroblasts found in these tissues have become increasingly important as investigation into the nature of organspecific autoimmune diseases proceeds. The concept that localization of systemic diseases could result, at least in part, from the peculiarities exhibited by fibroblasts in affected tissues continues to attract substantial discussion. However, significant advances have been made recently in our ability to distinguish between similarly appearing cells with 'fibroblast-like' morphologies. Despite these new insights, substantial imprecision persists in identifying the diverse biological roles of cells that resemble each other. At the heart of the problem lingers the absence of a single, specific marker that could distinguish fibroblasts from all other cells. Once characterized, such a protein would undoubtedly prove invaluable in elucidating more clearly the molecular mechanisms and cellular interactions that underlie normal and pathological tissue remodelling.
The orbital fibroblast: an example of cellular diversity
Orbital fibroblasts comprise a heterogeneous population of cells that can be separated into discrete subsets based on their display of surface markers [5] . The most frequently studied of these is Thy-1, which has been used by several investigators to discriminate between those fibroblasts that can differentiate into myofibroblasts (Thy-1 + ) and those capable of becoming adipocytes (Thy-1 -) [6, 7] . This assignment is also true for fibroblasts from lung [8, 9] . When Thy-1 + fibroblasts are exposed to transforming growth factor (TGF)-b, they differentiate into myofibroblasts. In contrast, Thy-1 remodelling observed in both anatomic regions. With regard to the orbit, the potential for Thy-1 -fibroblasts to differentiate into adipocytes might help to explain the apparent expansion of fat found in Graves' disease.
Infiltration of fibrocytes into tissues might contribute to apparent fibroblast diversity
Fibrocytes represent circulating bone-marrow derived monocyte lineage cells that present antigen efficiently to lymphocytes, prime naive T cells and can enter sites of tissue injury [10, 11] . They are distinct from fibroblasts, T and B lymphocytes, monocytes, epithelial, endothelial and dendritic cells and can differentiate into mature fat cells, osteoblasts and myofibroblasts. Their ultimate fate depends, at least in part, upon the signals they receive from their microenvironment and which of the intracellular signalling pathways become activated [12] . In this regard, fibrocytes resemble fibroblasts. Fibrocytes were first described by Bucalla et al. in 1994 as possessing a CD34
+ phenotype [10] , They were found capable of circulating as members of a population of peripheral blood mononuclear cells and were shown to enter wound chambers implanted in subcutaneous tissue. They were identified in connective tissue scars. Once fibrocytes have infiltrated injured target tissues undergoing remodelling, they assume a fibroblast-like morphology. Moreover, they appear to lose their surface expression of CD34 as they develop into fibroblasts [13] , suggesting that this protein behaves as a progenitor marker. Fibrocytes are believed to interact with other mononuclear cells that have also been recruited from the circulation. They can also cross-talk with residential fibroblasts. Currently it is uncertain exactly what roles fibrocytes play in tissue regeneration or how they might participate in the formation of fibrosis. Moreover, the mechanisms and signalling pathways through which they exchange molecular information with other cells are only partially identified. A major hurdle in characterizing fibrocytes and distinguishing them from fibroblasts continues to result from the absence of specific surface markers. Identification of fibrocytes as a distinct cell type has resulted from a rigorous set of characterization studies which should now allow greater precision in classifying their biological functions and attributing them to specific subpopulations of cells. A recent study by Pilling et al. [15] has examined the markers that might be useful in distinguishing human fibrocytes from fibroblasts. In their remarkably detailed and exhaustive study, the authors found that among the cell types examined, only fibrocytes express the combination of CD45RO, 25F9 and S100A8/A9. They included in their study fibroblasts, macrophages and peripheral blood monocytes. Importantly, they concluded that CD34, CD68 and collagen fail to discriminate among these four cell types. Several cytokines, including IFN-g, IL-4, IL-12, IL-13 and serum amyloid P, differentially affect the display of CD32, CD163, CD172a and CD206 in fibrocytes and macrophages [15] . Human fibrocytes express a diverse array of cytokines, including TNF-a, IL-1b, IL-10, monocyte chemoattractant protein (MCP), macrophage inflammatory protein (MIP)-1a, MIP-1b, MIP-2, platelet-derived growth factor (PDGF)-A, TGF-b1 and macrophage colony-stimulating factor (M-CSF). Moreover, treatment of fibrocytes with exogenous IL-1b induced IL-6, IL-8, IL-10, MCP-1, MIP-1a and MIP-1b. Thus the array of cytokines produced by fibrocytes, either under basal conditions or following activation by IL-1b, appears to be very similar to that found in fibroblasts originating from a variety of tissues.
Characterization of the fibrocyte phenotype
Regulation of fibrocyte trafficking to sites of injury and tissue repair apparently derives from a network of chemokines and chemoattractants. CXCR4 represents the principal chemokine receptor displayed on human fibrocytes. Its cognate ligand, CXCL12, is generated by several cell types. CXCL12 has been shown in several models to exert powerful Fibrocytes in autoimmune disease chemotactic influence by fibrocytes and represents a major determinant for their infiltration of target tissues. In addition, CCR3, CCR5 and CCR7 are also expressed on the human fibrocyte surface [16, 17] . A slightly different profile of receptors is found on animal fibrocytes. For instance, mouse fibrocytes display CXCR4, CCR2 and CCR7. PDGF, insulin-like growth factor (IGF) and epidermal growth factor (EGF) can induce CXCR4 mRNA [18] . Growth factor and hypoxia-driven CXCR4 display is mediated through the PI3 kinase/mTor pathway and can be inhibited by rapamycin, which substantially diminished the accumulation of fibrocytes in targeted tissues.
Evidence for fibrocyte involvement in human diseases
In the last few years, more attention has been focused upon the study of human fibrocytes and their potential abnormalities in disease. The research group led by Streiter has produced substantial evidence for fibrocytes playing an important role in lung fibrosis. In a series of reports, these investigators have demonstrated the remarkable plasticity with which fibrocytes can differentiate into either adipocytes or myofibroblasts, depending upon whether they are treated with an activator of PPARg or TGF-b [12, 19] . With regard to the former, troglitazone treatment resulted in the accumulation of lipid within the cytoplasm and the induction of the adipocyte-specific gene aP2. In contrast, activation of Smad2/3 and stress-activated protein kinase/c-Jun N-terminal kinase mitogen-activated protein kinase pathways results in the transition of fibrocytes to myofibroblasts and the induction of a-smooth muscle actin. The potential for fibrocyte participation in autoimmune disease remains relatively unexplored. Bohle and co-workers [20] examined the pathogenic basis for chronic renal failure developing as a consequence of primary glomerulopathies. They reported that renal insufficiency can result from chronically inflamed renal cortical post-glomerular capillaries. Vessel narrowing can impair glomerular perfusion. The authors found evidence suggesting that material reabsorbed by tubules could then be presented as autoantigens to intraepithelial T cells, leading potentially to immune responses involving expanded numbers of fibroblasts and fibrocytes. In an attempt to determine the propensity of marmosets to autoimmune disease, Maile and Merker described the tissue architecture of the thyroid [21] . They found monocytes, macrophages, mast cells and fibrocytes and speculated that these cells participate in the frequent thyroid autoimmunity found in these animals. Using phospho-specific flow cytometry, Galligan et al. examined peripheral blood fibrocytes from patients with established rheumatoid arthritis of greater than 1 year duration [22] . They reported that both p44/42 extracellular regulated (Erk) and p38 arms of the mitogen-activated protein kinase (MAPK) pathway were activated in these fibrocytes, as were signal transducer and activator of transcription (STAT) 3 and STAT5. The levels of phosphorylation found in early versus established rheumatoid arthritis were similar, suggesting that the levels of signalling might prove invariant following disease initiation. In a mouse model of sclerosing cholangitis, designated Abcb -/-, Roderfeld and colleagues were able to demonstrate the involvement of both bone marrow-derived fibrocytes and hepatic stellate cells in biliary fibrogenesis [23] .
Fibrocytes have been implicated in wound healing. This process is accelerated in mice deficient in leucocyte-specific protein 1 (LSP-1) [24] , a molecule purported to represent a reliable fibrocyte marker. It was also suggested that LSP-1 display might help to discriminate fibrocytes from fibroblasts [25] . LSP-1 null mice were found to have increased levels of macrophages, neutrophils and fibrocytes in full-thickness skin wounds. These tissues were also found to have elevated levels of TGF-b and vascular endothelial growth factor (VEGF) [24] . Similarly, bleomycin-induced fibrosis of the skin was enhanced in Lsp -/-mice [26] . Fibrocytes from patients with thermal burns and those from normal donors have substantially less capacity for collagen production than do dermal fibroblasts [27] . When conditioned medium from fibrocytes derived from burned individuals was incubated with dermal fibroblasts, they exhibited accelerated proliferation when compared to those incubated in medium from control fibrocytes. These effects could be blocked with TGF-b neutralizing antibodies [27] . These same investigators have shown that IFN-a2b can reduce scar formation following thermal injury by attenuating fibrocyte activity and reducing their numbers [28] .
With regard to the kidney, the participation of bone marrow-derived stem cells remains controversial [29] . Results generated in a number of models of renal injury suggest that these stem cells can localize to specific areas of the kidney and might facilitate tissue regeneration. Thus, their therapeutic potential in several forms of human kidney dysfunction is under evaluation. The outcome of such studies will probably influence the research being conducted in allied disease processes involving other organs and tissues.
Graves' disease as a model of fibrocyte participation in human autoimmunity: basis for orbital fibroblast heterogeneity?
Graves' disease represents an autoimmune process where the thyroid becomes enlarged and overactive [30] . The basis for the over-production of thyroid hormones and gland enlargement in this disease involves the production and activity of autoantibodies targeting the thyrotrophin (aka thyroidstimulating hormone) receptor (TSHR). In addition, the IGF-1 receptor (IGF-1R) is over-expressed by orbital fibroblasts [31] , B [32] and T cells [33, 34] in patients with the disease. IGF-1R represents a second potentially pathogenic autoantigen that may account for abnormal thyroid enlargement and underlie the trafficking of lymphocytes to affected tissues, including the pretibial skin and orbit. Pritchard et al. [31] have suggested that T cell trafficking to the orbit in Graves' disease might be mediated through fibroblast responses to IGF-1 and Graves' disease-immunoglobulin G (GD-IgG). When exposed to either agent, these fibroblasts express high levels of the T cell chemoattractants, IL-16 and regulated on activation normal T cell expressed and secreted (RANTES). The fibroblast response is mediated through IGF-1R activation and post-receptor signalling through the FRAP/mTor/Akt/p70 s6k pathway. It is absent in fibroblasts derived from healthy donors [35] . In addition to the generation of chemoattractants, thyroid-associated ophthalmopathy (TAO) orbital fibroblasts synthesize high levels of hyaluronan, in response to either GD-IgGs or IGF-1. Hyaluronan is a non-sulphated glycosaminoglycan, the accumulation of which is thought to result in tissue oedema [36] .
Orbital connective tissue derives in large part from neural ectoderm [37] . This tissue has a special propensity for inflammation. Approximately 30% of those individuals with Graves' disease also develop clinically important involvement of the orbit tissues surrounding the eye, a manifestation referred to as TAO. In this connective tissue component, the orbit becomes inflamed, and infiltrated with T and B lymphocytes and mast cells [38] . The cytokines and diseasemediating factors generated by these infiltrating cells are currently thought to activate resident fibroblasts which exhibit a unique phenotype. Orbital fibroblasts comprise a heterogeneous population of cells, especially those derived from patients with TAO [39] . The cellular attributes peculiar to orbital fibroblasts are thought to underlie the susceptibility of the orbit to the manifestations of Graves' disease. For instance, these fibroblasts exhibit particularly robust responses to proinflammatory cytokines such as the members of the IL-1 family. When activated by IL-1b, leucoregulin or CD154, orbital fibroblasts, especially those from patients with TAO, produce unusually high levels of hyaluronan [40] . This results from the induction of hyaluronan synthase (HAS) 1, 2 and 3 [41] and uridylyltransferase (UDP) glucose dehydrogenase [42] . The exaggerated induction of HAS isoforms could therefore account for the accumulation of hyaluronan in TAO. Activated orbital fibroblasts also express extremely high levels of IL-6, IL-8 and the prostaglandin endoperoxide H synthase-2, the inflammatory cyclooxygenase [43, 44] . This latter induction, in turn, results in the production of extraordinarily high levels of prostaglandin E2 (PGE2) [45] . The prostanoid can exert an important bias on immune responses occurring in the orbit and favour T helper type 2 (Th2) predominance [46] . The magnitude of the induction of proinflammatory cytokines by orbital fibroblasts is remarkable but poorly understood. Cao and Smith reported the relatively low levels of secreted IL-1 receptor antagonist (IL-1RA) produced by these cells [47] . Low levels of IL-1RA generation achieved following exposure to IL-1b results in poorly opposed IL-1a and IL-1b initiated signalling. Thus, the amplitude of cytokineprovoked downstream gene expression is substantially greater than that achieved in other fibroblast types. 
Fibrocytes in autoimmune disease
The basis for the heterogeneity displayed by orbital fibroblasts is yet to be understood [48] . When sorted on the basis of whether or not they display Thy-1 (CD90), orbital fibroblasts can be categorized broadly as those possessing the potential to become adipocytes (Thy-1 -) and those that can differentiate into myofibroblasts (Thy-1 + ) subsets [6] . Fibroblasts destined to become fat cells can do so spontaneously in culture or more efficiently when treated with prostacyclin together with compounds that increase intracellular cyclic adenosine-5′-monophosphate (cAMP) levels or with molecules that bind and activate PPAR g [6, 7] . Conversely, Thy-1 + fibroblasts differentiate into myofibroblasts that express high levels of smooth muscle actin. This occurs following their exposure to TGF-b. Accompanying their transition to adipocytes, levels of TSHR are increased substantially [49] , but what fibroblast subsets display TSHR specifically, and are these receptor molecules functional? Douglas and colleagues [50] have reported very recently that the frequency of fibrocytes circulating in patients with Graves' disease is elevated above the levels found in healthy individuals. As others have reported previously, this study suggested that fibrocyte generation from cultured peripheral blood mononuclear cells (PBMCs) derived from donors without any known chronic diseases were vanishingly rare. In contrast, cultured PBMCs from many patients with Graves' disease, regardless of duration, thyroidal status or treatment received, generated numerous fibrocytes that exhibited the expected CD34
+ phenotype. Interestingly, the elevated frequency of fibrocyte generation was not universal among patients with the disease. Many of these individuals, even those with recent onset and clinically severe disease, failed to generate fibrocytes at levels differing from those found in the control donors. The authors found relatively high levels of IGF-1R on fibrocytes, but the levels appear to be no different from those on fibrocytes donated by control subjects.
The report by Douglas et al. [50] began to characterize the phenotypic attributes of fibrocytes found in Graves' disease. Those studies aimed at identification of those cellular features that might underlie their participation in TAO. The authors found that CD34
IGF-1R
+ cells were relatively abundant in situ in orbital tissue from patients with TAO but were absent in those from healthy donors (Fig. 1 ). They were consistently CD31 -, indicating that the putative fibrocytes were unrelated to endothelial cells. Surprisingly, high levels of TSHR were detected on the circulating fibrocyte surface. The levels of this protein appear equivalent to those found on thyroid epithelial cells, where they mediate thyroid hormone production (Fig. 2) . Even more surprising was their observation that the receptor is functional. When ligated with bovine thyroid-stimulating hormone (bTSH) or M22, an activating monoclonal antibody generated against TSHR, the production of inflammatory cytokines such as TNF-a and IL-6 is up-regulated dramatically (Fig. 3) [50] . When orbital fibroblasts from patients with TAO were subjected to flow cytometric analysis, a subpopulation of cells was found to exhibit the CD34 +
Col1
+ phenotype. In contrast, CD34 + cells were uniformly absent among orbital fibroblasts from control donors. This phenotype was stable in culture over many serial passages. Moreover, it appears that the vast majority of CD34 + orbital fibroblasts are also CD90 + (Thy-1 + ). The finding that fibrocytes express high levels of TSHR and IGF-1R, coupled with their display of human leucocyte antigen D-related (HLA-DR), suggests that they might present autoantigens efficiently to T cells and in so doing could initiate antigen-specific immune responses. If this proves to be the case, the fibrocyte might represent an effective therapeutic target for early Graves' disease. As the phenotype of these cells becomes characterized more rigorously and the gene expression profile peculiar to fibrocytes becomes identified, it may be possible to target them with specific molecular probes. This strategy could yield individualized therapies.
Conclusions
The involvement of the orbit in Graves' disease can serve as a potentially important model for fibrocyte behaviour in autoimmune diseases. Moreover, the cellular diversity found among fibroblasts inhabiting the human orbit might, at least in part, be reconciled by the recruitment of fibrocytes and their differentiation into cells exhibiting distinct phenotypes. A schematic of our theoretical model for TAO and the putative involvement of fibrocytes in that disease process are presented in Fig. 4 . Orbital fibroblast diversity and their remarkable divergence from the phenotype more typically exhibited by fibroblasts from other tissues can, for the first time, be explained on the basis of their potential derivation from bone marrow-derived precursors. It is possible that this subset of fibroblasts is trafficked specifically to the orbit in TAO as a consequence of as-yet unidentified initiating processes. Once they have infiltrated the orbit, their potential * P < 0·001 * * * * P < 0·001 * * 450 for differentiation into either adipocytes or myofibroblasts may underlie the characteristic tissue remodelling that occurs in the disease. The relative frequency of fibrocytes and the phenotypic peculiarities exhibited by them could potentially explain why expansion of orbital fat might dominate the pathology of some patients with TAO while others manifest muscle-predominant disease. Moreover, identifying fibrocytes as playing a pathogenic role in TAO might allow them to be targeted by therapeutic agents, a strategy which has been proposed previously for other diseases involving tissue remodelling and fibrosis [17] . Layered onto these characteristics is the recent finding that TSHR is expressed at relatively high levels by these cells. This disease-specific autoantigen is functional in fibrocytes and could mediate cytokine production as a consequence of the activating autoantibodies directed against TSHR that are also responsible for the overactive thyroid in Graves' disease. This brings to light another heretofore unanticipated potential role for fibrocytes. Could these cells participate in the breakdown of immune tolerance of TSHR? Alternatively, could display of this protein on the surface of fibrocytes function to enhance peripheral tolerance? The recent findings by Douglas and colleagues suggest a number of testable hypotheses and could ultimately provide the overarching framework for Graves' disease and potentially other forms of autoimmunity.
